Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy

• Published in: Epilepsy & behavior 2024-10, Vol.159, p.109989, Article 109989
• Main Authors: Farkas, Mark Kristof, Makedonska, Iryna, Beller, Cynthia, Bourikas, Dimitrios, de la Loge, Christine, Dimova, Svetlana, Floricel, Florin, McClung, Carrie, Moseley, Brian, Therriault, Sheila, Pina-Garza, Jesus Eric
• Format: Article
• Language: English
• Subjects: Acetamides - administration & dosage; Acetamides - adverse effects; Acetamides - therapeutic use; Achenbach CBCL; Adolescent; Anticonvulsants - administration & dosage; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Antiseizure medication; BRIEF; Child; Child, Preschool; Epilepsy - drug therapy; Epilepsy - psychology; Executive Function - drug effects; Executive Function - physiology; Female; Focal-onset seizure; Follow-Up Studies; Generalized seizure; Humans; Infant; Lacosamide - administration & dosage; Lacosamide - adverse effects; Lacosamide - therapeutic use; Male; Seizure; Treatment Outcome
• ISSN: 1525-5050; 1525-5069; 1525-5069
• DOI: 10.1016/j.yebeh.2024.109989

[Display omitted] •Kaplan-Meier–estimated 1-year retention on lacosamide (LCM) was high (80%).•≥12-month seizure freedom was 29.9 %/24.4 % in focal-onset/generalized seizure population.•>75 % clinicians/caregivers reported improvements in patients during LCM treatment.•Long-term adjunctive LCM (median exposure: 679 days) was generally well tolerated.•Behavior and executive functioning were generally stable during long-term LCM treatment. To evaluate long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide (LCM) treatment in pediatric patients (≥1 month to 75 % of patients by both physicians and caregivers. Treatment-emergent adverse events (T